Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ therapeutic use
Chemotherapy, Adjuvant
/ methods
Clinical Trials as Topic
Cytoreduction Surgical Procedures
/ standards
Female
Humans
Maintenance Chemotherapy
/ methods
Medical Oncology
/ standards
Neoplasm Recurrence, Local
/ mortality
Ovarian Neoplasms
/ mortality
Poly(ADP-ribose) Polymerase Inhibitors
/ therapeutic use
Progression-Free Survival
Treatment Outcome
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
07
01
2019
accepted:
11
02
2019
pubmed:
22
3
2019
medline:
9
6
2020
entrez:
22
3
2019
Statut:
ppublish
Résumé
Staying current on the rapidly evolving therapeutic landscape in oncology is challenging for clinicians. This commentary discusses exciting practice‐changing data specific to ovarian cancer.
Identifiants
pubmed: 30894410
pii: theoncologist.2019-0020
doi: 10.1634/theoncologist.2019-0020
pmc: PMC6516122
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
576-579Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Br J Cancer. 2016 Nov 22;115(11):1313-1320
pubmed: 27824811
Gynecol Oncol. 2010 Jun;117(3):497-504
pubmed: 20363017
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Int J Surg Oncol. 2012;2012:613980
pubmed: 22919475
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Gynecol Oncol. 2013 Mar;128(3):573-8
pubmed: 23219660
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
J Clin Oncol. 2003 Jul 1;21(13):2460-5
pubmed: 12829663
Lancet Oncol. 2016 Nov;17(11):1579-1589
pubmed: 27617661
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Ann Oncol. 1997 Apr;8(4):327-33
pubmed: 9209661
J Clin Oncol. 2013 Apr 20;31(12):1554-61
pubmed: 23478059
Lancet Oncol. 2018 Aug;19(8):1117-1125
pubmed: 30026000
J Clin Oncol. 2007 Nov 20;25(33):5165-71
pubmed: 18024863
Lancet Oncol. 2018 Aug;19(8):1126-1134
pubmed: 30026002
Gynecol Oncol. 2016 Feb;140(2):199-203
pubmed: 26723501
J Clin Oncol. 2009 Jan 20;27(3):418-25
pubmed: 19075271
N Engl J Med. 1995 Apr 13;332(15):1004-14
pubmed: 7885406
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
pubmed: 15789122
Gynecol Oncol. 2015 Oct;139(1):10-6
pubmed: 26271155
Ann Oncol. 2012 Oct;23(10):2605-12
pubmed: 22910840
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Gynecol Oncol. 1993 Apr;49(1):30-6
pubmed: 8482557
Gynecol Oncol. 2017 Oct;147(1):3-10
pubmed: 28844539